Dogwood Therapeutics, Inc. is a pre-revenue, development-stage biopharmaceutical company focused on developing non-opioid medicines to treat pain and neuropathy. Its lead product, Halneuron (purified Tetrodotoxin), is in Phase 2b clinical trials for chemotherapy-induced neuropathic pain (CINP). The company also holds the SP16 program for neuropathy and nerve damage, and explores antiviral therapies for fibromyalgia and Long-COVID through partnership opportunities.
Q2 FY2026 — expected 2026-09-14
| Filed | Period | Accession | Source | Full Text |
|---|---|---|---|---|
| 2026-03-18 | 2025-12-31 | 0001104659-26-031061 | EDGAR | 77K words |
| 2025-03-31 | 2024-12-31 | 0001558370-25-004167 | EDGAR | 73K words |
| 2024-03-01 | 2023-12-31 | 0001558370-24-002239 | EDGAR | 59K words |
| 2023-03-14 | 2022-12-31 | 0001558370-23-003650 | EDGAR | 62K words |
| 2022-03-18 | 2021-12-31 | 0001558370-22-003885 | EDGAR | — |
| 2021-03-23 | 2020-12-31 | 0001558370-21-003366 | EDGAR | — |
| Filed | Period | Accession | Source | Full Text |
|---|---|---|---|---|
| 2026-08-14 | 2026-06-30 | 0001104659-26-096719 | EDGAR | 26K words |
| 2025-11-07 | 2025-09-30 | 0001104659-25-108169 | EDGAR | 25K words |
| 2025-08-13 | 2025-06-30 | 0001558370-25-011319 | EDGAR | 21K words |
| 2025-05-09 | 2025-03-31 | 0001558370-25-007109 | EDGAR | 20K words |
| 2024-11-08 | 2024-09-30 | 0001558370-24-014957 | EDGAR | 21K words |
| 2024-08-09 | 2024-06-30 | 0001558370-24-011686 | EDGAR | 12K words |
| 2024-05-10 | 2024-03-31 | 0001558370-24-007713 | EDGAR | 11K words |
| 2023-11-13 | 2023-09-30 | 0001558370-23-018708 | EDGAR | 12K words |
| 2023-08-11 | 2023-06-30 | 0001558370-23-014590 | EDGAR | 12K words |
| 2023-05-12 | 2023-03-31 | 0001558370-23-009516 | EDGAR | 9K words |
| 2022-11-14 | 2022-09-30 | 0001558370-22-017759 | EDGAR | — |
| 2022-08-12 | 2022-06-30 | 0001558370-22-013410 | EDGAR | — |
| Filed | Accession | Source | Full Text |
|---|---|---|---|
| 2026-08-13 | 0001104659-26-095512 | EDGAR | 2K words |
| 2026-03-26 | 0001104659-26-034928 | EDGAR | 1K words |
| 2026-03-18 | 0001104659-26-029992 | EDGAR | 2K words |
| 2026-03-12 | 0001104659-26-027090 | EDGAR | 1K words |
| 2026-01-20 | 0001104659-26-004838 | EDGAR | 1K words |
| 2026-01-13 | 0001104659-26-003211 | EDGAR | 1K words |
| 2025-11-28 | 0001104659-25-116865 | EDGAR | 21K words |
| 2025-11-21 | 0001104659-25-114919 | EDGAR | 8K words |
| 2025-11-06 | 0001104659-25-107471 | EDGAR | 2K words |
| 2025-10-09 | 0001104659-25-098360 | EDGAR | 4K words |
119 total filings indexed. 91 additional filings (S-1, DEF 14A, etc.) View all (JSON) · SEC EDGAR
| CIK | 0001818844 |
| Ticker | DWTX |
| Exchange | Nasdaq |
| SIC | 2834: Pharmaceutical Preparations |
| Incorporated | DE |
| Website | https://www.virios.com |
| Listed | 2020-12-17 |
This is a static snapshot. For live, structured JSON with cryptographic provenance chain:
MCP (recommended for AI): claude mcp add origin --transport http https://origin.rootz.global/mcp
Try it — paste this into your AI:
Works in ChatGPT, Claude, Gemini, or any AI. Free, structured, cryptographically signed — ~500 tokens vs 130,000 scraping an IR site.
claude mcp add origin --transport http https://origin.rootz.global/mcpGET https://origin.rootz.global/api/company/DWTX (~200 tokens, structured JSON with cryptographic provenance)